| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addressing overdiagnosis and overtreatment in cancer: a prescription for change
|
Esserman, Laura J
|
|
2014
|
15 |
6 |
p. e234-e242
|
artikel
|
| 2 |
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study
|
Corrie, Pippa G
|
|
2014
|
15 |
6 |
p. 620-630
|
artikel
|
| 3 |
Adjuvant chemotherapy for rectal cancer
|
Bujko, Krzysztof
|
|
2014
|
15 |
6 |
p. e194-e195
|
artikel
|
| 4 |
Adjuvant chemotherapy for rectal cancer
|
Atkins, Carl D
|
|
2014
|
15 |
6 |
p. e195-e196
|
artikel
|
| 5 |
Adjuvant chemotherapy for rectal cancer
|
Valsecchi, Matias E
|
|
2014
|
15 |
6 |
p. e195
|
artikel
|
| 6 |
Adjuvant chemotherapy for rectal cancer
|
Thornton, Michael
|
|
2014
|
15 |
6 |
p. e196
|
artikel
|
| 7 |
Adjuvant chemotherapy for rectal cancer
|
You, KaiYun
|
|
2014
|
15 |
6 |
p. e194
|
artikel
|
| 8 |
Adjuvant chemotherapy for rectal cancer – Authors' reply
|
Bosset, Jean-François
|
|
2014
|
15 |
6 |
p. e197-e198
|
artikel
|
| 9 |
Adjuvant therapy after hepatectomy for colorectal metastases
|
Fong, Yuman
|
|
2014
|
15 |
6 |
p. 544-545
|
artikel
|
| 10 |
Androgen deprivation therapy for early prostate cancer
|
Tanday, Sanjay
|
|
2014
|
15 |
6 |
p. e199
|
artikel
|
| 11 |
A new class of drug for advanced chronic myeloid leukaemia
|
Sharma, Sharan Prakash
|
|
2014
|
15 |
6 |
p. e200
|
artikel
|
| 12 |
Anti-androgen monotherapy for metastatic prostate cancer
|
Attard, Gerhardt
|
|
2014
|
15 |
6 |
p. 543-544
|
artikel
|
| 13 |
Bevacizumab plus chemotherapy for ovarian cancer
|
Ozkan, Judy
|
|
2014
|
15 |
6 |
p. e202
|
artikel
|
| 14 |
Cancer and couture: an unlikely partnership
|
Lucas, Catherine
|
|
2014
|
15 |
6 |
p. 566-567
|
artikel
|
| 15 |
Cancer prevention and care in India: an unfinished agenda
|
Sankaranarayanan, Rengaswamy
|
|
2014
|
15 |
6 |
p. 554-555
|
artikel
|
| 16 |
Cancer research in India: national priorities, global results
|
Sullivan, Richard
|
|
2014
|
15 |
6 |
p. e213-e222
|
artikel
|
| 17 |
Can NOAH guide us to improved survival in breast cancer?
|
Johnston, Stephen R D
|
|
2014
|
15 |
6 |
p. 550-552
|
artikel
|
| 18 |
Ceritinib: a safe and potent alternative to crizotinib
|
Bagcchi, Sanjeet
|
|
2014
|
15 |
6 |
p. e203
|
artikel
|
| 19 |
Chemotherapy before or after surgery for bladder cancer
|
Tanday, Sanjay
|
|
2014
|
15 |
6 |
p. e204
|
artikel
|
| 20 |
Companion imaging drug for treatment of ovarian cancer
|
Sharma, Sharan Prakash
|
|
2014
|
15 |
6 |
p. e203
|
artikel
|
| 21 |
Conventional stents versus stents loaded with 125iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trial
|
Zhu, Hai-Dong
|
|
2014
|
15 |
6 |
p. 612-619
|
artikel
|
| 22 |
Delivery of affordable and equitable cancer care in India
|
Pramesh, C S
|
|
2014
|
15 |
6 |
p. e223-e233
|
artikel
|
| 23 |
DNA test offers new option for colon cancer screening
|
Gilbert, Judith A
|
|
2014
|
15 |
6 |
p. e201
|
artikel
|
| 24 |
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study
|
Tombal, Bertrand
|
|
2014
|
15 |
6 |
p. 592-600
|
artikel
|
| 25 |
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
|
André, Fabrice
|
|
2014
|
15 |
6 |
p. 580-591
|
artikel
|
| 26 |
Exploring better strategies for EGFR antibodies in colon cancer
|
Cervantes, Andrés
|
|
2014
|
15 |
6 |
p. 549-550
|
artikel
|
| 27 |
Fukushima Daiichi: 3 years on
|
McCurry, Justin
|
|
2014
|
15 |
6 |
p. 556-557
|
artikel
|
| 28 |
Genetic drivers of angiosarcoma discovered
|
Bagcchi, Sanjeet
|
|
2014
|
15 |
6 |
p. e199
|
artikel
|
| 29 |
Hyperthermia in cancer: is it coming of age?
|
Januszewski, Adam
|
|
2014
|
15 |
6 |
p. 565-566
|
artikel
|
| 30 |
Inaccuracy of screening techniques for prostate cancer
|
Sharma, Sharan Prakash
|
|
2014
|
15 |
6 |
p. e204
|
artikel
|
| 31 |
Interleukin-1α neutralisation in patients with cancer
|
Dinarello, Charles Anthony
|
|
2014
|
15 |
6 |
p. 552-553
|
artikel
|
| 32 |
Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial
|
Wasan, Harpreet
|
|
2014
|
15 |
6 |
p. 631-639
|
artikel
|
| 33 |
Irradiation stents: a clever, and maybe costly, fusion
|
White, Russell E
|
|
2014
|
15 |
6 |
p. 546-547
|
artikel
|
| 34 |
Life and death in Hollywood
|
Harrison, Natalie
|
|
2014
|
15 |
6 |
p. 568
|
artikel
|
| 35 |
MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study
|
Hong, David S
|
|
2014
|
15 |
6 |
p. 656-666
|
artikel
|
| 36 |
Mining pollution: a legacy of contamination
|
Furlow, Bryant
|
|
2014
|
15 |
6 |
p. 558
|
artikel
|
| 37 |
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
|
Gianni, Luca
|
|
2014
|
15 |
6 |
p. 640-647
|
artikel
|
| 38 |
New drug for peripheral and cutaneous T-cell lymphomas
|
Sharma, Sharan Prakash
|
|
2014
|
15 |
6 |
p. e200
|
artikel
|
| 39 |
NICE guidance on aflibercept for treatment of metastatic colorectal cancer
|
Elsada, Ahmed
|
|
2014
|
15 |
6 |
p. 561-562
|
artikel
|
| 40 |
NICE guidance on bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem-cell transplantation
|
Griffiths, Christian
|
|
2014
|
15 |
6 |
p. 563-564
|
artikel
|
| 41 |
Omission of radiotherapy in PET-negative patients
|
Burki, Talha Khan
|
|
2014
|
15 |
6 |
p. e202
|
artikel
|
| 42 |
Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study
|
Castinetti, Frederic
|
|
2014
|
15 |
6 |
p. 648-655
|
artikel
|
| 43 |
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
|
Price, Timothy J
|
|
2014
|
15 |
6 |
p. 569-579
|
artikel
|
| 44 |
Real, raw, provocative: Breast Fest
|
Kukaswadia, Atif
|
|
2014
|
15 |
6 |
p. 567-568
|
artikel
|
| 45 |
Setting the bar for adjuvant treatment of melanoma
|
Sondak, Vernon K
|
|
2014
|
15 |
6 |
p. 547-548
|
artikel
|
| 46 |
Small-cell carcinoma of the ovary, hypercalcaemic type
|
Burki, Talha Khan
|
|
2014
|
15 |
6 |
p. e201
|
artikel
|
| 47 |
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial
|
Primrose, John
|
|
2014
|
15 |
6 |
p. 601-611
|
artikel
|
| 48 |
Targeting EGFR in colorectal cancer: beyond KRAS exon 2
|
Waddell, Tom
|
|
2014
|
15 |
6 |
p. 540-541
|
artikel
|
| 49 |
105th annual meeting of the AACR
|
Smith, Lan-Lan
|
|
2014
|
15 |
6 |
p. 560
|
artikel
|
| 50 |
The growing burden of cancer in India: epidemiology and social context
|
Mallath, Mohandas K
|
|
2014
|
15 |
6 |
p. e205-e212
|
artikel
|
| 51 |
9th European Breast Cancer Conference
|
Coburn, Cassandra
|
|
2014
|
15 |
6 |
p. 559
|
artikel
|
| 52 |
#trial: clinical research in the age of social media
|
The Lancet Oncology,
|
|
2014
|
15 |
6 |
p. 539
|
artikel
|
| 53 |
When is downstream pathway inhibition important?
|
Wilson, Sheridan
|
|
2014
|
15 |
6 |
p. 541-542
|
artikel
|
Tijdschrift beschrijving